GLP1R and metabolic dysfunction-associated steatohepatitis: In a phase 2 study, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) showed improvement in liver histology in individuals with NASH [20], in addition to improvement in cardiovascular and all-cause mortality in high-risk T2DM patients.